#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer
Click to read this study in The Lancet Oncology.
Click to read this study in The Lancet Oncology.
1. Almost half of patients (47%) had either an objective response or had progression free survival for at least 6 ...
1. Disease control was reported in over half of the patients treated with abemaciclib 2. Most common adverse events included ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.